Extracellular Vesicles in Acute Kidney Injury and Clinical Applications DOI Open Access
Sekyung Oh, Sang‐Ho Kwon

International Journal of Molecular Sciences, Journal Year: 2021, Volume and Issue: 22(16), P. 8913 - 8913

Published: Aug. 18, 2021

Acute kidney injury (AKI)––the sudden loss of function due to tissue damage and subsequent progression chronic disease––has high morbidity mortality rates is a serious worldwide clinical problem. Current AKI diagnosis, which relies on measuring serum creatinine levels urine output, cannot sensitively promptly report the state damage. To address shortcomings these traditional diagnosis tools, several molecular biomarkers have been developed facilitate identification ensuing monitoring AKI. Nanosized membrane-bound extracellular vesicles (EVs) in body fluids emerged as excellent sources for discovering such biomarkers. Besides this diagnostic purpose, EVs are also being extensively exploited deliver therapeutic macromolecules damaged cells ameliorate Consequently, many successful biomarker findings applications based made. Here, we review our understanding how can help with early accurate be used therapeutically. We will further discuss where current EV-based fall short future innovations could lead us.

Language: Английский

Extracellular vesicles in kidney disease DOI Open Access
Cristina Grange, Benedetta Bussolati

Nature Reviews Nephrology, Journal Year: 2022, Volume and Issue: 18(8), P. 499 - 513

Published: May 31, 2022

Language: Английский

Citations

119
Nanomaterials for Targeted Therapy of Kidney Diseases: Strategies and Advances DOI Creative Commons
Zhiwen Wang, Chun Zhang

Materials Today Bio, Journal Year: 2025, Volume and Issue: 31, P. 101534 - 101534

Published: Jan. 29, 2025

The treatment and management of kidney diseases pose a significant global burden. Due to the presence blood circulation barriers glomerular filtration barriers, drug therapy for faces challenges such as poor renal targeting, short half-life, severe systemic side effects, severely hindering therapeutic progress. Therefore, research development kidney-targeted agents is great clinical significance. In recent years, application nanotechnology in field nephrology has shown potential revolutionizing diagnosis diseases. Carefully designed nanomaterials can exhibit optimal biological characteristics, influencing various aspects circulation, retention, excretion. Rationally designing modifying based on anatomical structure pathophysiological environment achieve highly specific or nanodrug delivery systems both feasible promising. Based targeted diseases, this review discusses advantages limitations current nanomedicine summarizes active/passive targeting strategies, order further promote through preliminary summary previous studies future prospects.

Language: Английский

Citations

2
Rapidly Blocking the Calcium Overload/ROS Production Feedback Loop to Alleviate Acute Kidney Injury via Microenvironment‐Responsive BAPTA‐AM/BAC Co‐Delivery Nanosystem DOI

Jiahui Yan,

Yanan Wang, Jingwen Zhang

et al.

Small, Journal Year: 2023, Volume and Issue: 19(17)

Published: Jan. 31, 2023

Abstract Calcium overload and ROS overproduction, two major triggers of acute kidney injury (AKI), are self‐amplifying mutually reinforcing, forming a complicated cascading feedback loop that induces cell “suicide” ultimately renal failure. There currently no clinically effective drugs for the treatment AKI, excluding adjuvant therapy. In this study, porous silicon‐based nanocarrier rich in disulfide bond skeleton (<50 nm) is developed enables efficient co‐loading hydrophilic drug borane amino complex hydrophobic BAPTA‐AM, with its outer layer sealed by tubule‐targeting peptide PEG‐LTH. Once targeted to injured site, structure collapses high glutathione environment early stage releasing drugs. Under action slightly acidic inflammatory intracellular esterase, released produce hydrogen BAPTA, which can rapidly eliminate excess overloaded Ca 2+ , blocking endoplasmic reticulum/mitochondrial apoptosis pathway (ATF4‐CHOP‐Bax axis, Casp‐12‐Casp‐3 Cyt‐C‐Casp‐3 axis) (TNF‐α‐NF‐κB from source, thus rescuing cells “critical survival” state further restoring function. Overall, nanoparticle shows substantial clinical promise as potential therapeutic strategy I/R injury‐related diseases.

Language: Английский

Citations

23
Sensing Dying Cells in Health and Disease DOI Creative Commons

Elena Tutunea-Fatan,

Shabitha Arumugarajah,

Rita S. Suri

et al.

Journal of the American Society of Nephrology, Journal Year: 2024, Volume and Issue: 35(6), P. 795 - 808

Published: Feb. 14, 2024

Kidney injury molecule-1 (KIM-1), also known as T-cell Ig and mucin domain-1 (TIM-1), is a widely recognized biomarker for AKI, but its biological function less appreciated. KIM-1/TIM-1 belongs to the domain family of conserved transmembrane proteins, which bear characteristic six-cysteine Ig-like variable domain. The latter enables binding natural ligand, phosphatidylserine, expressed on surface apoptotic cells necrotic cells. in variety tissues plays fundamental roles regulating sterile inflammation adaptive immune responses. In kidney, KIM-1 upregulated injured renal proximal tubule cells, transforms them into phagocytes clearance dying helps dampen inflammation. TIM-1, T B killer essential cell activation regulatory functions host. Functional polymorphisms gene KIM-1/TIM-1, HAVCR1 , have been associated with susceptibility immunoinflammatory conditions hepatitis A virus-induced liver failure, thought be due differential ability variants bind phosphatidylserine. This review will summarize role health disease potential clinical applications therapeutic target humans.

Language: Английский

Citations

14
High-density lipoprotein nanoparticles spontaneously target to damaged renal tubules and alleviate renal fibrosis by remodeling the fibrotic niches DOI Creative Commons
Shanshan He, Xiaoyang Li, Yuanyuan He

et al.

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: Jan. 27, 2025

Chronic kidney disease (CKD) ultimately causes renal fibrosis and end-stage disease, thus seriously threatens human health. However, current medications for CKD are inefficient, which is often due to poor targeting capability tubule. In this study, we discover that biomimetic high-density lipoprotein (bHDL) lipid nanoparticles possess excellent ability injured tubular epithelial cells by injury molecule-1(KIM-1) mediated internalization. Thus, co-load anti-inflammatory drug triptolide (TP) anti-fibrotic nintedanib (BIBF) on bHDL treat CKD. Based the targeted delivery mutual enhancement of efficacy co-delivered drugs, bHDL-based system effectively reduces alleviates in different mouse models. The mechanistic study shows BIBF TP synergistically remodel fibrotic niches decreasing inflammatory cytokines, limiting immune cell infiltration inhibiting activation myofibroblasts. vehicle also possesses high manufacturability, good safety adequately toxicity TP. promising treatment has potential delivering agents damaged cells. Effectively tubule delay or halt chronic progression remains a significant unmet clinical challenge. Here, authors introduce an innovative strategy using nanoparticles.

Language: Английский

Citations

1
The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review DOI Creative Commons
Mohammed Almulhim

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(1), P. e0311755 - e0311755

Published: Jan. 29, 2025

Acute kidney injury (AKI) is a frequent clinical complication lacking early diagnostic tests and effective treatments. Novel biomarkers have shown promise for enabling earlier detection, risk stratification, guiding management of AKI. We conducted systematic review to synthesize evidence on the efficacy novel AKI detection management. Database searches yielded 17 relevant studies which were critically appraised. Key themes biomarker in predicting severity before functional changes; potential improve through diagnosis, prognostic enrichment, interventions; emerging roles as therapeutic targets tools; ongoing challenges requiring further validation. Overall, like neutrophil gelatinase-associated lipocalin (NGAL), molecule-1 (KIM-1), cell cycle arrest markers ([TIMP-2] •[IGFBP7]) demonstrate capability very prediction accurate stratification. Their incorporation has facilitate timely targeted interventions personalized However, factors influencing performance, optimal cutoffs, cost-effectiveness, impact patient outcomes require robust validation across diverse settings widespread implementation. Addressing these limitations research can help translate into improved prognosis, practice.

Language: Английский

Citations

1
Engineered Macrophage Membrane-Coated Nanoparticles Attenuate Calcium Oxalate Nephrocalcinosis-Induced Kidney Injury by Reducing Oxidative Stress and Pyroptosis DOI

Xiaozhuo Ba,

Tao Ye,

Yu He

et al.

Acta Biomaterialia, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

1
Emerging Frontiers in acute kidney injury: The role of extracellular vesicles DOI
Sirui Li, Lan Zhou, Yu Huang

et al.

Bioactive Materials, Journal Year: 2025, Volume and Issue: 48, P. 149 - 170

Published: Feb. 18, 2025

Language: Английский

Citations

1
Mesenchymal cell-derived exosomes and miR-29a-3p mitigate renal fibrosis and vascular rarefaction after renal ischemia reperfusion injury DOI Creative Commons
Jing Huang, Lang Shi, Yifei Yang

et al.

Stem Cell Research & Therapy, Journal Year: 2025, Volume and Issue: 16(1)

Published: March 12, 2025

Renal fibrosis and vascular rarefaction are significant complications of ischemia/reperfusion (I/R) injury. Human umbilical cord mesenchymal cell-derived exosomes (hucMSC-exos) have shown potential in mitigating these conditions. This study investigates the role miR-29a-3p its therapeutic effects on I/R-induced renal damage. Male C57BL/6 mice were subjected to unilateral ischemia for 28 min followed by reperfusion. Exosomes mimics/inhibitors injected into mice. function, histological analysis, molecular assays performed evaluate integrity. Exosome treatment significantly improved function reduced post-I/R. MiR-29a-3p was highly expressed hucMSC-exos but models. mimic reduced, while inhibitor exacerbated rarefaction. Collagen I TNFR1 identified as direct targets fibroblasts endothelial cells, respectively. overexpressing provided superior protection compared unmodified hucMSC-exos. HucMSC-exos, particularly those miR-29a-3p, potent against collagen I, highlighting therapy.

Language: Английский

Citations

1
Lipid-Based Nanovesicular Drug Delivery Systems DOI Creative Commons
Tania Limongi, Francesca Susa, Monica Marini

et al.

Nanomaterials, Journal Year: 2021, Volume and Issue: 11(12), P. 3391 - 3391

Published: Dec. 14, 2021

In designing a new drug, considering the preferred route of administration, various requirements must be fulfilled. Active molecules pharmacokinetics should reliable with valuable drug profile as well well-tolerated. Over past 20 years, nanotechnologies have provided alternative and complementary solutions to those an exclusively pharmaceutical chemical nature since scientists clinicians invested in optimization materials methods capable regulating effective delivery at nanometer scale. Among many carriers, lipid nano vesicular ones successfully support clinical candidates approaching such problems insolubility, biodegradation, difficulty overcoming skin biological barriers blood-brain one. this review, authors discussed structure, biochemical composition, applications nanovesicular namely, niosomes, proniosomes, ethosomes, transferosomes, pharmacosomes, ufasomes, phytosomes, catanionic vesicles, extracellular vesicles.

Language: Английский

Citations

45